5,6-Bis-(4-chlorophenyl)pyrazine-2-carbothioic acid cyclohexylamide | 1056554-92-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5,6-Bis-(4-chlorophenyl)pyrazine-2-carbothioic acid cyclohexylamide
• 英文别名: 5,6-di-(4-chlorophenyl)pyrazine-2-carbothioic acid cyclohexylamide；5,6-bis(4-chlorophenyl)-N-cyclohexylpyrazine-2-carbothioamide
• CAS: 1056554-92-7
• 化学式: C₂₃H₂₁Cl₂N₃S
• 分子量: 442.412
• InChiKey: HLJFBDANUXYSFO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.4
• 重原子数：
  29
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  69.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  C₂₃H₂₁Cl₂N₃O 在 劳森试剂 作用下， 以 甲苯 为溶剂， 反应 0.17h， 生成 5,6-Bis-(4-chlorophenyl)pyrazine-2-carbothioic acid cyclohexylamide
  参考文献：
  名称：

  Novel thioamide derivatives as neutral CB1 receptor antagonists

  摘要：

  A novel class of cannabinoid-1 (CB1) receptor antagonists for the treatment of obesity is presented. The carboxamide linker in a set of 5,6-diaryl-pyrazine-2-amide derivatives was transformed into the corresponding thioamide, by using a one-pot synthesis. The structural series of thioamides not only showed retained CB1 potency (below 10 nM), but also showed improved solubility. In addition, the neutral antagonist 2c significantly reduced body weight in cafeteria diet obese mice. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.11.125

文献信息

• THERAPEUTIC AGENTS
  申请人：Bostrom Jonas

  公开号：US20090156616A1

  公开（公告）日：2009-06-18

  The present invention relates to compounds of formula (I) and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them.

  本发明涉及式（I）的化合物及制备这些化合物的方法，它们在治疗肥胖、精神疾病和神经系统疾病中的应用，以及它们的治疗应用方法和含有它们的制药组合物。
• [EN] THERAPEUTIC AGENTS<br/>[FR] AGENTS THERAPEUTIQUES
  申请人：ASTRAZENECA AB

  公开号：WO2007010222A2

  公开（公告）日：2007-01-25

  [EN] The present invention relates to compounds of formula (I) and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them.
  [FR] L'invention concerne des composés représentés par la formule (I) ainsi que des procédés permettant de préparer lesdits composés, leur utilisation dans le traitement de l'obésité et des troubles psychiatriques et neurologiques, des méthodes pour leur utilisation thérapeutique et des compositions pharmaceutiques contenant lesdits composés.